Landmark cardiovascular outcome trials including EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin), and DECLARE-TIMI 58 (dapagliflozin) demonstrated that SGLT2 inhibitors (SGLT2i) reduce major adverse cardiovascular events (MACE) in high-risk patients, and robustly reduce heart failure hospitalizations and progression of kidney disease in broader population [9,10,11]. Here, SLC5A2 is linked to heart failure.